| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d0fc2b70675ee19bd5fc464f5ae9061 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a92751f66edead9d856fff5266c0a15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4b43dcf94403917405165ca6be8b18d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04cd1973643e8e5451189cef6c047b5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40d9c03ac38ebcb8e7f66212dbf6a054 |
| publicationDate |
2022-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20220164413-A |
| titleOfInvention |
Composition for preventing or treating fibrosis comprising an inhibitor of cyclin-dependent kinase 17 expression or activity |
| abstract |
The present invention relates to a composition for preventing or treating fibrosis comprising a CDK17 (cyclin-dependent kinase 17) expression or activity inhibitor. In the present invention, hepatic stellate cells in which CDK17 expression or activity inhibitors were activated (hepatic fibrosis cell model), renal tubular epithelial cells induced fibrosis by treatment with TGF-β (renal fibrosis cell model), and fibrosis by treatment with TGF-β By confirming that collagen production, activity, and viability of reactive alveolar epithelial cells (pulmonary fibrosis cell model) are significantly reduced, it has a very excellent effect for preventing or treating fibrosis. |
| priorityDate |
2021-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |